NCT00967941

Completed

Vancomycin and Daptomycin Plus Cefazolin for Preoperative Va...

CAMC Health System Source

Compare

Other study identifiers

Sponsor study identifier

06-11-1879

Study Type

observational

Actual enrollment (reported)

169

Locations

1 country

Sites

1

Timeline

Study Start

August 2007

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

June 2009

Actual (reported)

Study Completion

August 2010

Actual (reported)

Brief Summary

This study prospectively selects the patients to examine the effectiveness of the investigators' current standard of prophylaxis prior to vascular surgery and to compare the effectiveness of vancomycin and daptomycin plus cefazolin in reducing infections in vascular surgical patients.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 169 participants
Study completion date: August 2010
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
August 2007
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
June 2009
Actual (reported)
First Submitted
August 27, 2009
Actual (reported)
First Posted
August 28, 2009
Actual (reported)
Study Completion
August 2010
Actual (reported)
Results Posted
February 28, 2020
Actual (reported)

Last Updated: September 14, 2026
Status Verified: February 2020
Results QC Date: February 16, 2020
Last Update Submitted: August 20, 2026

Conditions

MRSA Infections

Keywords

Vascular Surgery

Outcome Measures

Primary Outcomes (1)

Overall Number of Participants With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections.
30 days post-operative

Secondary Outcomes (1)

Overall Groin Procedures in Patients With and Without Any Infection.
30 days post-operative

Study Arms (3)

Ancef

Vancomycin and Cefazolin

Daptomycin and Cefazolin

Eligibility Criteria

Age18 Years - 90 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients 18 years of age and older undergoing a vascular surgery and or vascular access (vascular fistula or vascular graft) procedure were eligible for enrollment in the study.

You may qualify if:

Patients greater than 18 years of age undergoing vascular surgery including carotid procedures and a vascular access procedure (Fistula or Graft).

Sponsors & Collaborators

CAMC Health System
Otherlead

Study Sites (1)

Vascular Center of Excellence

Charleston, West Virginia, 25304, United States

Limitations and Caveats

We did not have standardization of skin preparation. Additionally, we did not have a specific protocol for dressing use and time of dressing removal. We excluded high-risk patients for MRSA infection in our study.

Results Point of Contact

Title: Patrick Stone, MD
Organization: CAMC Health System

Study Officials

Patrick Stone, M.D.
CAMC Medical Staff-with admitting privileges
PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee: Yes
Restrictive Agreement: No

Enrollment

169 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 27, 2009

First Posted

August 28, 2009

Study Start

August 2007

Date type not reported

This date has not been verified as actual or estimated.

You may not qualify if:

Patients with an allergy to daptomycin or vancomycin.
Patients with chronic wounds.
Prior colonization of MRSA.
Increased MRSA rate facility wide.
Continuous inpatient stay \>27 hrs prior to surgical procedure.
Patients with active infection requiring antibiotics preoperatively.
Patients with a history of MRSA colonization or infection, HIV, admission for \>3 months in an acute care center or long-term care center, penicillin allergy or penicillin allergy and on dialysis.
Dialysis patients.

Contact the study team to confirm eligibility.

Primary Completion

June 2009

Actual (reported)

Study Completion

August 2010

Actual (reported)

Last Updated

September 14, 2026

Results First Posted

February 28, 2020

Record last verified: 2020-02

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00967941
Data provider: ClinicalTrials.gov
Source updated: 2026-09-14
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:38:27 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

First Submitted

First Posted

Study Completion

Results Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (3)

Ancef

Vancomycin and Cefazolin

Daptomycin and Cefazolin

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Limitations and Caveats

Results Point of Contact

Study Officials

Publication Agreements

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations